Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin and LDN for COVID-19
NCT04604678Phase 2Withdrawn
- Sponsor
- AgelessRx
- Start
- Feb 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of metformin and naltrexone in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by AgelessRx. Primary endpoint: Reduction of COVID-19 symptoms at 2 weeks. Planned start Feb 2021; status: withdrawn.
02
Drugs
metforminnaltrexone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04604678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04604678.